Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2

Status

Completed 6Recruiting 5Withdrawn 2Unknown 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Locally Advanced Unresectable Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Ramucirumab × Clear all
NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03739801 2020-03-27

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

University of Southern California

Phase 1/2 Withdrawn
Gastrointestinal

Locally Advanced Unresectable Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡